|
1
|
Nicholson AG, Tsao MS, Beasley MB, Borczuk
AC, Brambilla E, Cooper WA, Dacic S, Jain D, Kerr KM, Lantuejoul S,
et al: The 2021 WHO classification of lung tumors: Impact of
advances since 2015. J Thorac Oncol. 17:362–387. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nambirajan A and Jain D: Recent updates in
thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn
Pathol. 38:83–89. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jiang J, Chen Z, Gong J, Han N and Lu H:
Thoracic SMARCA4-deficient undifferentiated tumor. Discov Oncol.
14:512023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li X, Tian S, Shi H, Ta N, Ni X, Bai C,
Zhu Z, Chen Y, Shi D, Huang H, et al: The golden key to open
mystery boxes of SMARCA4-deficient undifferentiated thoracic tumor:
Focusing immunotherapy, tumor microenvironment and epigenetic
regulation. Cancer Gene Ther. 31:687–697. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Longo V, Catino A, Montrone M, Montagna
ES, Pesola F, Marech I, Pizzutilo P, Nardone A, Perrone A, Gesualdo
M and Galetta D: Treatment of thoracic SMARCA4-deficient
undifferentiated tumors: Where we are and where we will go. Int J
Mol Sci. 25:32372024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang D and Wang Y: Imaging performance of
thoracic SMARCA4-deficient undifferentiated tumor: A case report
and literature review. Transl Lung Cancer Res. 13:443–452. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nagendrababu V, Chong BS, McCabe P, Shah
PK, Priya E, Jayaraman J, Pulikkotil SJ and Dummer PMH: PRICE 2020
guidelines for reporting case reports in Endodontics: Explanation
and elaboration. Int Endod J. 53:922–947. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Patriarcheas V, Grammoustianou M, Ptohis
N, Thanou I, Kostis M, Gkiozos I, Charpidou A, Trontzas I, Syrigos
N, Kotteas E and Dimakakos E: Malignant superior vena cava
syndrome: State of the art. Cureus. 14:e209242022.PubMed/NCBI
|
|
9
|
Quencer KB: Superior vena cava syndrome:
etiologies, manifestations, and treatments. Semin Intervent Radiol.
39:292–303. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun L, Fu Q, Chen L, Di M and Cao J:
SMARCA4-deficient non-small cell lung cancer with an EGFR mutation:
A case report. Oncol Lett. 26:5132023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lin Y, Yu B, Sun H, Zhang H, Hu Z, Zhang
Y, Wu Z, Sun S, Zhao X, Yu H, et al: Promising efficacy of immune
checkpoint inhibitor plus chemotherapy for thoracic
SMARCA4-deficient undifferentiated tumor. J Cancer Res Clin Oncol.
149:8663–8671. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oncology Society of Chinese Medical
Association and Chinese Medical Association Publishing House, .
Chinese Medical Association guideline for clinical diagnosis and
treatment of lung cancer (2023 edition). Zhonghua Zhong Liu Za Zhi.
45:539–574. 2023.(In Chinese). PubMed/NCBI
|
|
13
|
Wang A, Jin Y, Cao Z, Lu L and Li Z:
Clinicopathological characteristics and treatment outcomes of
advanced SMARCA4-deficient thoracic tumors. Cancer Med.
13:e68092024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shi L, Lin L, Ding Y, Zeng Y and Chen X:
Case report: A rapid response to immunotherapy in a thoracic
SMARCA4-deficient undifferentiated tumor with respiratory failure.
Front Oncol. 12:10208752022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang P, Xiong F, Lin Y, Liang P and Tang
C: Effectiveness of tislelizumab when combined with etoposide and
carboplatin in patients with SMARCA4-deficient undifferentiated
thoracic tumor: A case report. Transl Cancer Res. 12:1041–1048.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Naito T, Umemura S, Nakamura H, Zenke Y,
Udagawa H, Kirita K, Matsumoto S, Yoh K, Niho S, Motoi N, et al:
Successful treatment with nivolumab for SMARCA4-deficient non-small
cell lung carcinoma with a high tumor mutation burden: A case
report. Thorac Cancer. 10:1285–1288. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kunimasa K, Okami J, Takenaka S, Honma K,
Kukita Y, Nagata S, Kawamura T, Inoue T, Tamiya M, Kuhara H, et al:
Conversion surgery for advanced thoracic SMARCA4-deficient
undifferentiated tumor with atezolizumab in combination with
bevacizumab, paclitaxel, and carboplatin treatment: A case report.
JTO Clin Res Rep. 2:1002352021.PubMed/NCBI
|
|
18
|
Gantzer J, Davidson G, Vokshi B,
Weingertner N, Bougoüin A, Moreira M, Lindner V, Lacroix G, Mascaux
C, Chenard MP, et al: Immune-desert tumor microenvironment in
thoracic SMARCA4-deficient undifferentiated tumors with limited
efficacy of immune checkpoint inhibitors. Oncologist. 27:501–511.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ablation Expert Committee of the Chinese
Society of Clinical Oncology and Expert Group on Tumor Ablation
Therapy of the Chinese Medical Doctors Association; Society of
Tumor Ablation Therapy of the Chinese Anti-Cancer Association;
Tumor Ablation Committee of the Chinese College of
Interventionalists, . Clinical practice guidelines:image-guided
thermal ablation of primary and metastatic lung tumors (2021
edition). Zhonghua Nei Ke Za Zhi. 60:1088–1105. 2021.(In Chinese).
PubMed/NCBI
|
|
20
|
Tatli S, Tapan U, Morrison PR and
Silverman SG: Radiofrequency ablation: Technique and clinical
applications. Diagn Interv Radiol. 18:508–516. 2012.PubMed/NCBI
|
|
21
|
Cariati M, Giordano G, Midulla M, Calati
AM, Sacrini A, Raveglia F and Cornalba GP: Radiofrequency ablation
of pulmonary lesions. Radiol Med. 112:149–156. 2007.(In English,
Italian). View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kwak KJ, Yu B, Lewandowski RJ and Kim DH:
Recent progress in cryoablation cancer therapy and nanoparticles
mediated cryoablation. Theranostics. 12:2175–2204. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tatli S, Acar M, Tuncali K, Morrison PR
and Silverman S: Percutaneous cryoablation techniques and clinical
applications. Diagn Interv Radiol. 16:90–95. 2010.PubMed/NCBI
|
|
24
|
Wright K, Digby GC, Gyawali B, Jad R,
Menard A, Moraes FY and Wijeratne DT: Malignant superior vena cava
syndrome: A scoping review. J Thorac Oncol. 18:1268–1276. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Azizi AH, Shafi I, Zhao M, Chatterjee S,
Roth SC, Singh M, Lakhter V and Bashir R: Endovascular therapy for
superior vena cava syndrome: A systematic review and meta-analysis.
EClinicalMedicine. 37:1009702021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azizi AH, Shafi I, Shah N, Rosenfield K,
Schainfeld R, Sista A and Bashir R: Superior vena cava syndrome.
JACC Cardiovasc Interv. 13:2896–2910. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wong HCY, Chan AW, David E, Marta GN, Pan
NY, Koller M, Lim F, Yeung R, Chow E and Simone CB II: Should
endovascular stenting be used routinely as first-line treatment for
malignant superior vena cava syndrome?-a critical review in the
context of recent advances in oncological treatments. Ann Palliat
Med. 12:803–815. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ratzon R, Tamir S, Friehmann T, Livneh N,
Dudnik E, Rozental A, Hamburger-Avnery O, Pereg D, Derazne E,
Brenner B, et al: Thrombosis, anticoagulation and outcomes in
malignant superior vena cava syndrome. J Thromb Thrombolysis.
47:121–128. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gorospe L, Ajuria-Illarramendi O,
Lage-Alfranca Y and Martín-Martín M: Differentiation of bland
versus tumor thrombus in a lung cancer patient with an implanted
central venous access device and a superior vena cava syndrome:
18F-FDG PET/CT findings. Jpn J Clin Oncol. 52:96–97. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tathireddy H, Rice D, Martens K,
Shivakumar S and Shatzel J: Breaking down tumor thrombus: Current
strategies for medical management. Thromb Res. 230:144–151. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Serena G, Gonzalez J, Gaynor JJ, Salerno
T, Verzaro R and Ciancio G: Pulmonary tumor embolization as early
manifestation in patients with renal cell carcinoma and tumor
thrombus: Perioperative management and outcomes. J Card Surg.
34:1018–1023. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xu Y and Li M: Updated interpretation of
Chinese Society of Clinical Oncology (CSCO) guidelines for the
diagnosis and treatment of non-small cell lung cancer 2024. J Mod
Med Health. 40:1801–1808. 2024.(In Chinese).
|
|
33
|
Liang X, Zheng T, Ge Q and Huang R:
Effective management of SMARCA4-deficient undifferentiated tumor by
immunotherapy combined with chemotherapy and radiotherapy: Case
report. Medicine (Baltimore). 104:e457472025. View Article : Google Scholar : PubMed/NCBI
|